Active — Not RecruitingPhase 3

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

United States705 participantsStarted 2023-02-27

Plain-language summary

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of Motion Sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI \> 40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

What they're measuring

Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).

Timeframe: through study completion, approximately 1 year

Trial details

NCT IDNCT06138613

SponsorVanda Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-09-30

View on ClinicalTrials.gov More Motion Sickness trials